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Therapeutic inertia amongst general practitioners with interest in diabetes. 
Introduction/Background 
As the armamentarium of therapeutic options in management of type 2 diabetes increases, 
there is an increasingly complex range of options which can create confusion among health 
care professionals leading to the phenomenon of therapeutic inertia. Therapeutic inertia is 
defined as the failure of healthcare professionals to initiate or intensify or de-intensify 
therapy when indicated1,2. Early in the disease, there are clear guidelines about diet and 
lifestyle modifications and the use of oral hyperglycaemic agents (OHAs)3. As the disease 
progresses and there are increasing comorbidities such as renal and cardiovascular disease, a 
more individualised approach to treatment is required. For example, in older patients4, 
quality of life becomes a more important factor. Therapeutic inertia could be due to a lack of 
training or knowledge, difficulty accessing specialist care advice in a timely manner or 
deviation from clinical guidelines5. There are also wider system level factors in therapeutic 
inertia such as the high cost of newer agents6. 
Therapeutic inertia is present at all levels of treatment, although, it manifests at a higher level 
when injectable therapies are indicated. Studies in the UK have shown there was a delay in 
intensification for patients on one OHA with an HbA1c >7% (>53 mmol/mol) of 1.6 years, 
compared with >6.9 years for those taking two OHAs7. The median time to intensification with 
insulin was >7.1, >6.1, or 6.0 years for those taking one, two, or three OADs7. 
The delay in intensification leaves a hyperglycaemic legacy which acounts for the 
complications later in the disease8. Therapeutic inertia has been shown to lead to an increase 
risk of myocardial infarction by 67% (CI 39 W101%), stroke by 51% (CI 25 W83%), heart failure 
by 64% (CI 40 W91%) and with a composite cardiovascular events by 62% (CI 46 W80%) in people 
with type 2 diabetes with a HbA1c of >7% and not receiving treatment intensification within 
1 year were8.  
Since therapeutic inertia has been blamed on the lack of training or knowledge and the 
difficulty in accessing specialist care advice in a timely manner, it is worth up skilling the 
primary care base to prevent the phenomenon. This will bring not only clinical benefits to the 
patients, but also financial benefits to the health system and the providers.  To our 
knowledge, therapeutic inertia has never been reported in any studies focusing solely on 
primary care physicians with an interest in diabetes, however, this group is increasingly 
becoming the focus of managing complex diabetes care in the community, albeit with the 
support from specialists9-13.  
Therefore, in this study, we sought to assess the prevalence of the phenomenon of 
therapeutic inertia amongst primary care physicians with interest in diabetes in the UK. We 
also assessed the predictive abilities of various patient level characteristics on therapeutic 
inertia amongst this group of clinicians. When there has not been intensification of treatment, 
we assessed if this was due to the knowledge of the clinical context of the patient by the 
clinician.  
In this study, we defined intensification or de-intensification as the change of a therapeutic 
dose of existing glucose lowering drug or addition or withdrawal of another glucose lowering 
drug. This may not always occur, but that is not always therapeutic inertia, as there may be 
other clinical reasons such as the patient being stated to be within an individualised 
acceptable target of glycaemic control. Therapeutic inertia is failure to intensify or de-
intensify treatment when there is a clinical justification for this to occur. Broadly, 
 ?/ŶƚĞŶƐŝĨŝĐĂƚŝŽŶ ? refers to situations when the patient is less than 65 years and HbA1c has 
remain more than 53mmol/mol (7%) for more than twelve months when there is no risk of 
hypoglycaemia - this represents those who are younger, and may require tightening of 
treatment to achieve recommended HbA1c control. ͞De-intensification ? refers to those over 
65 years and have risk of hypoglycaemia but have HbA1c less than 53 mmol/mol (7%) yet no 
treatment change occurred in past 12 months  W this group represents those who clinically may 
need a higher HbA1c targets and may be candidates for treatment relaxation. 
 
Methods 
Primary care physicians with interest in diabetes across the UK were invited for this quality 
assurance programme. These clinicians were identified through the Primary Care Academy of 
Diabetes Specialists (PCADS). At the time of the study, the group consisted of 27 general 
practitioners with interests in diabetes in the UK who liaise with others to foster 
understanding on the key elements essential for delivering a diabetes service and the 
potential challenges involved. Between January and March 2016, each participating clinician 
retrospectively audited the last twenty consecutive patients with type 2 diabetes seen in their 
clinic. From this audit, they assessed if therapeutic inertia had occurred or not, based broadly 
on the aforementioned definitions, and their holistic knowledge of the patients. Anonymised 
demographic, biochemical and pharmacological data were extracted by the individual 
clinicians and assembled for analysis. The variables extracted included age, sex, duration of 
diabetes (date of diagnosis), stated glycated haemoglobin (HbA1c) target, Last recorded 
Hba1c, number of oral hypoglycaemic agents, glucagon-like peptide 1 (GLP-1) receptor 
agonists and insulin.  
Statistical analysis. 
Data were analysed using SPSS for Windows (version 22, SPSS Inc., Chicago, IL, USA). The 
categorical variables were reported as numbers (percentages) and the continuous variables 
as means (standard deviations).  For the continuous demographic variables, independent 
sample t-tests we performed between the groups of patients in whom therapeutic inertia 
occurred and those it did not. For the categorical variables, we used the chi-squared test to 
compare the various demographic and pharmacological variables between those in whom 
therapeutic inertia was present and those in whom it was not. Logistic regression was used 
to assess whether the eight variables together as a model or individually could distinguish 
between situations in which therapeutic inertia occurred and when it did not occur, after 
ensuring there was no significant interactions between the independent variables.  
 
Results 
In total, there were twelve respondents from England, Wales and Northern Ireland, each 
supplying data for twenty patients with type 2 diabetes. Four of the respondents were female 
and eight were male. Four worked in rural practices and the other eight worked in urban 
inner-city practices. All the respondents worked in the National Health Service (NHS). Out of 
the 240 patients reported on, therapeutic inertia was judged to have occurred in 53 (22.1%) 
of patient. Table 1 illustrates the detail characteristics used in the analysis. The mean age of 
the patients was 62.2 years (standard deviation (SD) of 12.10). The group had a mean duration 
of diabetes of 9.9 years. The mean of their most recent HbA1c was 70.8 mmol/mol, (SD=16.5). 
On the average, their target HbA1c set in partnership with their clinicians was 56.2 mmol/mol.  
Except for the duration of diabetes, there were no differences in these demographic 
characteristics between the patients in whom therapeutic inertia occurred and those in whom 
it did not occur. 
In the patients in whom therapeutic inertia was occurred, there was an increased male 
preponderance (58.5%). Also, 15 (28.3%) of them were on triple oral therapies, 19 (35.8 %) 
on dual therapies and 14 (26.4%) on mono therapy. Only 4 (7.5%) of them were on GLP1 
agonist and 12 (22.6%) were on insulin.  
We assessed whether there was an association between therapy intensification or de-
intensification and therapeutic inertia. There was a significant association between 
therapeutic inertia and whether therapy was intensified or not, p=0.000. Only in 37.6% of the 
population of patients in whom therapy was not intensified did the clinicians demonstrate 
therapeutic inertia, implying that in almost two-thirds of people in whom therapy was not 
intensified, there was a clinical justification for that decision. 
As shown in table 2, the full model containing all the 8 variables was not statistically 
significant, p=0.59. So, the model was not able to distinguish between situations in which 
therapeutic inertia occurred and when it did not occur in the general practitioners with 
interest in diabetes. None of the patient level characteristics on its own was predictive of 
therapeutic inertia. No significant association between therapeutic inertia and the number of 
oral hypoglycaemic agents, p=0.062. 
 
Discussion 
Among general practitioners with interest in diabetes care, the problem of therapeutic inertia 
occurred only in a little over a fifth of the patients.  This is contrasted with findings in purely 
generalist practitioners14. 
Not many studies have attempted to quantify the prevalence of inertia in any setting.  
However, in a multispecialty group practice in Michigan between 2000 and 2005, 27% of 
patients had periods of sustained hyperglycaemia, defined as two A1C values of >8% with no 
intervening medication intensification15.  In another previous study in the US, a comparison 
was done on the management of a people with diabetes from a deprived population in a 
primary care site supervised by general internal medicine faculty, and the Diabetes Clinic, a 
specialty site supervised by endocrinologists. Use of pharmacotherapy including less use of 
insulin, was less intensive in the primary care site14. Even when patients had raised glucose 
levels in clinic, therapy was less than half as likely to be escalated in the primary care centre 
compared to the Diabetes Clinic (P < .0001), regardless of the type of therapy considered. The 
HbA1c averaged 8.6% in the primary care centre versus 7.7% in the Diabetes Clinic (p < .0001). 
Thus, the more specialised the clinical team, the less likely the issue of therapeutic inertia14. 
In our evaluation, in the situations when the therapeutic inertia has occurred, it is difficult to 
identify a single most important contributing factor. However, it appears that, often, when 
therapy intensification does not occur, they may be a clinical justification for this. 
The relatively less frequent occurrence of therapeutic inertia amongst primary care clinicians 
with an interest in diabetes in this study could be attributed to many factors not accounted 
for in this evaluation. First, unlike the generalist physician in primary care that may be running 
a generalist clinic and seeing patients with multiple medical problems, the generalist with 
interest in diabetes may selectively have a separate diabetes clinic. In these clinics, they would 
focus on diabetes in a lot of detail, albeit with consideration for other competing multi-morbid 
conditions, and thus more likely to suggest medication intensification or de-intensification in 
patients with inadequate glycaemic targets. In a study on 211 consultations in people with 
type 2 diabetes in primary care, it was noted that for people with HbA1c levels above 7%, 
each additional patient concern was associated with a 49% less likelihood of changes in 
medications independently of the level of Hba1c or length of consultation16, 
Second, the relationship between the unit costs of drugs for diabetes and therapeutic clinical 
inertia remains largely unknown. In most areas, choice of regimen is influenced by prescribing 
budgets. In England, most areas will have some newer antidiabetic agents reserved for 
prescribing by only specialists either in secondary care centres on primary care centres. 
Ideally, patients should receive an antidiabetic drug regimen that is consistent with safe and 
timely correction of blood glucose, regardless of cost. This ideal however is seldom exercised 
by the generalist physician. It is very possible that with the increasing long-term effects of 
suboptimal glycaemic control, the rising medico-legal costs of therapeutic inertia may 
encourage greater prioritisation of therapeutic inertia during patient-physician contacts, 
irrespective of whether they are specialist of not17. In the UK, claims against healthcare 
professionals involving diabetes increased by 28%, from 162 during 2003-2007 to 207 in 2008-
201218.  
Third, psychological or physical stresses in patients have been cited as one of the reasons for 
therapeutic inertia19. When the clinician has a holistic knowledge of ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
biopsychosocial state, they can judge a level of control as adequate for that patient even if 
there is poor control, especially in the geriatric population. It is possible that social 
undesirability may have led to not intensifying treatment, leaving only more socially 
acceptable reasons.  
Finally, if health care organisation that promote the use of primary care physicians with 
specific interest in diabetes, can demonstrate less therapeutic inertia, it is hoped that this will 
translate in better outcomes for the patients at a lesser cost for the society. In Australia, 
researchers recently demonstrated that an innovative integrated primary Wsecondary model 
of care for people with complex type 2 diabetes could lead to fewer admissions for a diabetes-
related complication and the care provided at a cheaper cost than those receiving usual 
care10,20,21. Similarly, after a similar evaluation, researchers in England also suggested that the 
use of well-trained, well-organised primary care teams, offering enhanced diabetes care, has 
the potential to lead to longer lasting benefits22. 
 
Strengths and limitations 
To our knowledge, this is the first study to look at the phenomenon of therapeutic inertia 
amongst primary care physicians with interest in diabetes. In an era where diabetes 
management is increasingly being conducted in primary care settings by enhanced primary 
care teams22, the findings in this evaluation supports diabetes care models that are led by 
generalists with specialist interest in diabetes. Another strength of this evaluation is that the 
respondents were clinicians practicing in England, Northern Ireland and Wales, thus making 
the findings grossly generalizable to these home countries in the UK.  
The main limitation of our study is the small number of participating clinicians who also 
merely did a self-reporting of whether therapeutic inertia occurred or not. To make the results 
more generalizable, it would have been better to have a larger sample of generalists with 
specialist interest in diabetes responding the audit request.  Additionally, there is no generally 
accepted definition for a generalist with specialist interest in diabetes. The respondents all 
have varying levels of expertise in clinical diabetes, either through working alongside 
specialist colleagues or through further academic training in diabetes. As there is no standard 
accreditation for this role, it is difficult to attribute the results of this evaluation wholly to 
generalists with special interest in diabetes.  
 
Conclusion 
Therapeutic inertia is present only in about a fifth of patient patients with diabetes being 
managed by primary care physicians with interest in diabetes. Often times, when there has 
been lack of intensification of therapy, there was a clinical justification for that decision. 
Patient level characteristics studied here have not predicted the inertia.  
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